BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:JNJ-87189401 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of JNJ-87189401\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06095089-11223@assetmemo.bio
DTSTAMP:20261121T005738Z
DTSTART;VALUE=DATE:20270621
DTEND;VALUE=DATE:20270622
SUMMARY:JNJ-87189401: Phase 1 readout est. (NCT06095089)
DESCRIPTION:JNJ-87189401\, phase 1\, Prostate Cancer.\nStudy: A Study of JN
 J-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer\nEstima
 ted primary completion: 21 June 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/jnj-87189401#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06095089
URL:https://assetmemo.bio/drug/jnj-87189401#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07082920-11223@assetmemo.bio
DTSTAMP:20261121T005738Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:JNJ-87189401: Phase 1 readout est. (NCT07082920)
DESCRIPTION:JNJ-87189401\, phase 1\, Prostate Cancer.\nStudy: A Study of JN
 J-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Canc
 er\nEstimated primary completion: 30 November 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/jnj-87189401#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07082920
URL:https://assetmemo.bio/drug/jnj-87189401#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07164443-11223@assetmemo.bio
DTSTAMP:20261121T005738Z
DTSTART;VALUE=DATE:20280818
DTEND;VALUE=DATE:20280819
SUMMARY:JNJ-87189401: Phase 3 readout est. (NCT07164443)
DESCRIPTION:JNJ-87189401\, phase 3\, Prostate Cancer.\nStudy: A Study of Pa
 sritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metasta
 tic Castration-resistant Prostate Cancer (mCRPC)\nEstimated primary comple
 tion: 18 August 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /jnj-87189401#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07164443
URL:https://assetmemo.bio/drug/jnj-87189401#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
